Literature DB >> 17409138

Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses.

David Derse1, Bruce Crise, Yuan Li, Gerald Princler, Nicole Lum, Claudia Stewart, Connor F McGrath, Stephen H Hughes, David J Munroe, Xiaolin Wu.   

Abstract

Retroviral integration into the host genome is not entirely random, and integration site preferences vary among different retroviruses. Human immunodeficiency virus (HIV) prefers to integrate within active genes, whereas murine leukemia virus (MLV) prefers to integrate near transcription start sites and CpG islands. On the other hand, integration of avian sarcoma-leukosis virus (ASLV) shows little preference either for genes, transcription start sites, or CpG islands. While host cellular factors play important roles in target site selection, the viral integrase is probably the major viral determinant. It is reasonable to hypothesize that retroviruses with similar integrases have similar preferences for target site selection. Although integration profiles are well defined for members of the lentivirus, spumaretrovirus, alpharetrovirus, and gammaretrovirus genera, no members of the deltaretroviruses, for example, human T-cell leukemia virus type 1 (HTLV-1), have been evaluated. We have mapped 541 HTLV-1 integration sites in human HeLa cells and show that HTLV-1, like ASLV, does not specifically target transcription units and transcription start sites. Comparing the integration sites of HTLV-1 with those of ASLV, HIV, simian immunodeficiency virus, MLV, and foamy virus, we show that global and local integration site preferences correlate with the sequence/structure of virus-encoded integrases, supporting the idea that integrase is the major determinant of retroviral integration site selection. Our results suggest that the global integration profiles of other retroviruses could be predicted from phylogenetic comparisons of the integrase proteins. Our results show that retroviruses that engender different insertional mutagenesis risks can have similar integration profiles.

Entities:  

Mesh:

Year:  2007        PMID: 17409138      PMCID: PMC1900082          DOI: 10.1128/JVI.02752-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Targeting retroviral integration?

Authors:  Frederic Bushman
Journal:  Mol Ther       Date:  2002-11       Impact factor: 11.454

2.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

3.  HIV-1 integration in the human genome favors active genes and local hotspots.

Authors:  Astrid R W Schröder; Paul Shinn; Huaming Chen; Charles Berry; Joseph R Ecker; Frederic Bushman
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

4.  Gene therapy put on hold as third child develops cancer.

Authors:  Erika Check
Journal:  Nature       Date:  2005-02-10       Impact factor: 49.962

5.  HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells.

Authors:  Peter Cherepanov; Goedele Maertens; Paul Proost; Bart Devreese; Jozef Van Beeumen; Yves Engelborghs; Erik De Clercq; Zeger Debyser
Journal:  J Biol Chem       Date:  2002-10-28       Impact factor: 5.157

6.  Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor signal transduction is associated with reduced LAT and phospholipase Cgamma1 phosphorylation.

Authors:  J E Baker; R Majeti; S G Tangye; A Weiss
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

7.  Host sequences flanking the human T-cell leukemia virus type 1 provirus in vivo.

Authors:  I Leclercq; F Mortreux; M Cavrois; A Leroy; A Gessain; S Wain-Hobson; E Wattel
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors.

Authors:  D Derse; S A Hill; P A Lloyd; B A Morse
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  A long terminal repeat retrotransposon of fission yeast has strong preferences for specific sites of insertion.

Authors:  Teresa L Singleton; Henry L Levin
Journal:  Eukaryot Cell       Date:  2002-02

10.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728

View more
  85 in total

Review 1.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

2.  Chromodomains direct integration of retrotransposons to heterochromatin.

Authors:  Xiang Gao; Yi Hou; Hirotaka Ebina; Henry L Levin; Daniel F Voytas
Journal:  Genome Res       Date:  2008-02-06       Impact factor: 9.043

Review 3.  Integration site selection by retroviral vectors: molecular mechanism and clinical consequences.

Authors:  René Daniel; Johanna A Smith
Journal:  Hum Gene Ther       Date:  2008-06       Impact factor: 5.695

4.  Integration of reporter transgenes into Schistosoma mansoni chromosomes mediated by pseudotyped murine leukemia virus.

Authors:  Kristine J Kines; Maria E Morales; Victoria H Mann; Geoffrey N Gobert; Paul J Brindley
Journal:  FASEB J       Date:  2008-04-10       Impact factor: 5.191

5.  Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.

Authors:  Hui Fen Zhao; Allistair Abraham; Yoon-Sang Kim; Yong-Dong Wang; Tamara Pestina; Jun Zhan; Keith Humphries; Arthur W Nienhuis; Derek A Persons
Journal:  Mol Ther       Date:  2017-02-09       Impact factor: 11.454

6.  Proviruses selected for high and stable expression of transduced genes accumulate in broadly transcribed genome areas.

Authors:  Jirí Plachy; Jan Kotáb; Petr Divina; Markéta Reinisová; Filip Senigl; Jirí Hejnar
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

7.  Integration of exogenous DNA into mouse embryonic stem cell chromosomes shows preference into genes and frequent modification at junctions.

Authors:  Keiichiro Suzuki; Fumi Ohbayashi; Itoshi Nikaido; Akihiko Okuda; Haruyoshi Takaki; Yasushi Okazaki; Kohnosuke Mitani
Journal:  Chromosome Res       Date:  2010-02-23       Impact factor: 5.239

8.  Upregulation of human T-cell leukemia virus type 1 antisense transcription by the viral tax protein.

Authors:  Sébastien Landry; Marilène Halin; Amandine Vargas; Isabelle Lemasson; Jean-Michel Mesnard; Benoit Barbeau
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration.

Authors:  Yasuhiro Koh; Xiaolin Wu; Andrea L Ferris; Kenneth A Matreyek; Steven J Smith; KyeongEun Lee; Vineet N KewalRamani; Stephen H Hughes; Alan Engelman
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors.

Authors:  Thomas R Bauer; James M Allen; Mehreen Hai; Laura M Tuschong; Iram F Khan; Erik M Olson; Rima L Adler; Tanya H Burkholder; Yu-Chen Gu; David W Russell; Dennis D Hickstein
Journal:  Nat Med       Date:  2007-12-23       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.